» Articles » PMID: 16491295

Glucocorticoid-treated Mice Have Localized Changes in Trabecular Bone Material Properties and Osteocyte Lacunar Size That Are Not Observed in Placebo-treated or Estrogen-deficient Mice

Overview
Date 2006 Feb 24
PMID 16491295
Citations 139
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: This study compares changes in bone microstructure in 6-month-old male GC-treated and female ovariectomized mice to their respective controls. In addition to a reduction in trabecular bone volume, GC treatment reduced bone mineral and elastic modulus of bone adjacent to osteocytes that was not observed in control mice nor estrogen-deficient mice. These microstructural changes in combination with the macrostructural changes could amplify the bone fragility in this metabolic bone disease.

Introduction: Patients with glucocorticoid (GC)-induced secondary osteoporosis tend to fracture at higher bone mineral densities than patients with postmenopausal osteoporosis. This suggests that GCs may alter bone material properties in addition to BMD and bone macrostructure.

Materials And Methods: Changes in trabecular bone structure, elastic modulus, and mineral to matrix ratio of the fifth lumbar vertebrae was assessed in prednisolone-treated mice and placebo-treated controls for comparison with estrogen-deficient mice and sham-operated controls. Compression testing of the third lumbar vertebrae was performed to assess whole bone strength.

Results: Significant reductions in trabecular bone volume and whole bone strength occurred in both prednisolone-treated and estrogen-deficient mice compared with controls after 21 days (p < 0.05). The average elastic modulus over the entire surface of each trabecula was similar in all the experimental groups. However, localized changes within the trabeculae in areas surrounding the osteocyte lacunae were observed only in the prednisolone-treated mice. The size of the osteocyte lacunae was increased, reduced elastic modulus around the lacunae was observed, and a "halo" of hypomineralized bone surrounding the lacunae was observed. This was associated with reduced (nearly 40%) mineral to matrix ratio determined by Raman microspectroscopy. These localized changes in elastic modulus and bone mineral to matrix ratio were not observed in the other three experimental groups.

Conclusions: Based on these results, it seems that GCs may have direct effects on osteocytes, resulting in a modification of their microenvironment. These changes, including an enlargement of their lacunar space and the generation of a surrounding sphere of hypomineralized bone, seem to produce highly localized changes in bone material properties that may influence fracture risk.

Citing Articles

Decreasing miR-433-3p Activity in the Osteoblast Lineage Blunts Glucocorticoid-mediated Bone Loss.

Thakore P, Karki S, Hrdlicka H, Garcia-Munoz J, Pereira R, Delany A Endocrinology. 2025; 166(2).

PMID: 39820728 PMC: 11791524. DOI: 10.1210/endocr/bqaf008.


Eucommia ulmoides Oliver polysaccharide alleviates glucocorticoid-induced osteoporosis by stimulating bone formation via ERK/BMP-2/SMAD signaling.

Song J, Zhang Y, Jin X, Zhu Y, Li Y, Hu M Sci Rep. 2024; 14(1):29647.

PMID: 39609585 PMC: 11604974. DOI: 10.1038/s41598-024-80859-4.


The osteocytic actions of glucocorticoids on bone mass, mechanical properties, or perilacunar remodeling outcomes are not rescued by PTH(1-34).

Yee C, Meliadis C, Kaya S, Chang W, Alliston T Front Endocrinol (Lausanne). 2024; 15:1342938.

PMID: 39092287 PMC: 11291448. DOI: 10.3389/fendo.2024.1342938.


Aging decreases osteocyte peri-lacunar-canalicular system turnover in female C57BL/6JN mice.

Vahidi G, Boone C, Hoffman F, Heveran C Bone. 2024; 186:117163.

PMID: 38857854 PMC: 11227388. DOI: 10.1016/j.bone.2024.117163.


Bioinformatics analysis of PANoptosis regulators in the diagnosis and subtyping of steroid-induced osteonecrosis of the femoral head.

Ding Q, Xiong B, Liu J, Rong X, Tian Z, Chen L Medicine (Baltimore). 2024; 103(18):e37837.

PMID: 38701259 PMC: 11062652. DOI: 10.1097/MD.0000000000037837.


References
1.
Saag K . Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003; 32(1):135-57, vii. DOI: 10.1016/s0889-8529(02)00064-6. View

2.
Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P . Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003; 18(6):1051-6. DOI: 10.1359/jbmr.2003.18.6.1051. View

3.
van Staa T, Laan R, Barton I, Cohen S, Reid D, Cooper C . Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003; 48(11):3224-9. DOI: 10.1002/art.11283. View

4.
Kinney J, Habelitz S, Marshall S, Marshall G . The importance of intrafibrillar mineralization of collagen on the mechanical properties of dentin. J Dent Res. 2003; 82(12):957-61. DOI: 10.1177/154405910308201204. View

5.
Lane N, Yao W, Kinney J, Modin G, Balooch M, Wronski T . Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J Bone Miner Res. 2003; 18(12):2105-15. DOI: 10.1359/jbmr.2003.18.12.2105. View